The new company will be based at GSK's Stevenage research centre north of London, with a second research hub in South San Francisco. GSK first unveiled its ambitions in bioelectronics in a paper in the journal Nature three years ago and believes it is ahead of Big Pharma rivals in developing medicines that use electrical impulses rather than traditional...